Improving Visual Attention in Schizophrenia

NCT ID: NCT03880227

Last Updated: 2021-07-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-25

Study Completion Date

2020-03-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates whether visual attention can be improved in individuals with schizophrenia by stimulating the brain via transcranial Direct Current Stimulation (tDCS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Individuals with schizophrenia tend to display abnormal visual attention when performing visual tasks, typically spending less time on salient features of the stimuli (e.g. core facial features or body movement in social tasks), and instead focusing on idiosyncratic features of an image or video. Poor visual attention in schizophrenia has been directly linked to poorer social cognitive performance (e.g. recognizing emotional expressions or social cues) which can impact an individual's day to day functioning.

Transcranial Direct Current Stimulation (tDCS) is a form of noninvasive neurostimulation which has been proposed as a therapeutic procedure in numerous psychiatric disorders. TDCS in schizophrenia has been demonstrated to improve a wide range of cognitive processes, and in healthy adults, tDCS has been demonstrated to improve aspects of social cognition. TDCS thus appears to be a promising therapeutic technique that may be useful for improving visual attention in patients with schizophrenia, and potentially impact social cognitive performance via an underlying mechanism tying the two. This study will compare visual performance in individuals with schizophrenia across two conditions: active anodal tDCS and sham tDCS, while also comparing between brain stimulation sites: rTPJ and dmPFC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Schizoaffective Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Participants will be paired based on key demographic criteria and assigned to one of two stimulation locations (rTPJ or dmPFC), participants will then complete active and sham stimulation sessions in a randomized, counterbalanced order approximately one week apart.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anodal followed by sham stimulation tDCS to rTPJ

cross-over design - active stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the rTPJ followed by behavioral testing.

Group Type EXPERIMENTAL

Active anodal tDCS

Intervention Type DEVICE

active anodal tDCS with behavioral tasks to assess visual attention

Sham tDCS

Intervention Type DEVICE

sham tDCS with behavioral tasks to assess visual attention

Anodal followed by sham stimulation tDCS to dmPFC

cross-over design - active stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the dmPFC followed by behavioral testing.

Group Type ACTIVE_COMPARATOR

Active anodal tDCS

Intervention Type DEVICE

active anodal tDCS with behavioral tasks to assess visual attention

Sham tDCS

Intervention Type DEVICE

sham tDCS with behavioral tasks to assess visual attention

Sham followed by anodal stimulation tDCS to rTPJ

cross-over design - sham stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week delay, active stimulation tDCS to the rTPJ followed by behavioral testing.

Group Type EXPERIMENTAL

Active anodal tDCS

Intervention Type DEVICE

active anodal tDCS with behavioral tasks to assess visual attention

Sham tDCS

Intervention Type DEVICE

sham tDCS with behavioral tasks to assess visual attention

Sham followed by anodal stimulation tDCS to dmPFC

cross-over design - sham stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week delay, active stimulation tDCS to the dmPFC followed by behavioral testing.

Group Type ACTIVE_COMPARATOR

Active anodal tDCS

Intervention Type DEVICE

active anodal tDCS with behavioral tasks to assess visual attention

Sham tDCS

Intervention Type DEVICE

sham tDCS with behavioral tasks to assess visual attention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active anodal tDCS

active anodal tDCS with behavioral tasks to assess visual attention

Intervention Type DEVICE

Sham tDCS

sham tDCS with behavioral tasks to assess visual attention

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-IV-TR or DSM-5 diagnosis of schizophrenia or schizoaffective disorder and clinically stable (i.e. no hospitalizations) for at least 8 weeks prior to informed consent and be on a stable medication regimen for at least 6 weeks with no dose changes for a minimum of 2 weeks prior to informed consent.

Exclusion Criteria

* The presence or history of a pervasive developmental disorder or mental retardation as defined by a premorbid IQ \< 70
* Presence or history of medical or neurological disorders in which neural stimulation would be contraindicated (e.g. presence of epilepsy or history of seizures)
* Presence of sensory limitations, including visual or hearing impairments that interfere with assessment
* History of electroconvulsive therapy
* Not proficient in English
* Presence of substance abuse in the past one month or dependence not in remission in the past six months
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The University of Texas at Dallas

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hans Klein

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hans S Klein, MS

Role: PRINCIPAL_INVESTIGATOR

University of Texas at Dallas

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Texas at Dallas

Richardson, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

19-58

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HD-tDCS for Hallucinations
NCT06208176 NOT_YET_RECRUITING NA